Veracyte plans to highlight data from six poster abstracts regarding its Decipher urologic cancer tests at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium to be held both virtually and in San Francisco.
The abstracts report results from a phase III study that evaluated the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from diagnostic biopsy specimens, Veracyte said.
